![Page 1: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/1.jpg)
Symptoms, assessment and treatment options for Ovarian
Cancer Dr. Naven Chetty
Gynaecological Oncologist
Queensland Centre for Gynaecological Oncology
Bridges Health Service
Mater Public and Private Hospitals
![Page 2: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/2.jpg)
Introduction
• Median age of diagnosis- 53
• Age-adjusted incidence- 12.8 per 100,000 per year
• 1 in 72 women will be diagnosed with cancer of the ovary during their lifetime
• Second most common gynaecological malignancy
• The most common cause of death among women who develop gynaecological malignancies
• Fifth leading cause of cancer death in females in the United States
![Page 3: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/3.jpg)
Introduction
• The mean age of diagnosis of epithelial ovarian cancer is in the mid-fifties
• Risk of malignancy of adnexal mass in per-menopause is 6-11%, in post-menopause is 29-35%
![Page 4: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/4.jpg)
Risk factors
• Nulligravity
• Early menache and late menopause
• Postmenopausal oestrogen replacement therapy
• Genetic
• Endometriosis
• Talc- small increase risk(RR 1.4)
• Cigarette smoking- mucinous cancer(RR 2.1) dose related
• Obesity-small but significant increase risk with BMI >/= 30, obesity also increases relative risk of death from ovarian cancer
![Page 5: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/5.jpg)
Genetic factors
• Mutations and/or over expression of the oncogenes- HER2 c-myc and K-ras, Akt, and of the tumour suppressor gene p53 have frequently been observed in sporadic ovarian cancer
• Inactivation of the tumour suppressor genes PTEN and p16 may occur
• BRAC 1 and 2 are implicated in small proportion of cases
![Page 6: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/6.jpg)
Protective factors
• OCP- relative risk of 0.64, occurs after 3-6 months of use and lasts for 15yrs after cessation
• Multiparity
• Tubal ligation- reduces risk by 1/3( if BRAC1 carrier by 60%)
• Breastfeeding
• Progesterone
![Page 7: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/7.jpg)
Symptoms
• Ill-defined- therefore advanced at time of presentation
• Rupture or torsion are unusual
• Abdo distension
• Nausea
• Anorexia
• Early satiety due to ascites, omental or bowel metastases
• Dyspnoea due to pleural effusions
![Page 8: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/8.jpg)
Symptoms
• lower abdominal pain/discomfort/pressure/bloating
• Increased abdominal size
• Constipation
• Lack of appetite/nausea/indigestion
• Irregular menstrual cycles/abnormal vaginal bleeding
• Low back pain
• Fatigue
• Urinary frequency
• Dyspareunia
![Page 9: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/9.jpg)
Symptoms
• Paraneoplastic syndrome-• Uncommon
• Hypercalcemia- clear cell EOC
• Sub-acute cerebellar degeneration
• Leser-trelat sign- sudden appearance of multiple seborrheic keratoses
• Trousseau’s sign- migratory thrombophlebitis
![Page 10: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/10.jpg)
Assessment
• Examination
• Ultrasound most useful non-invasive test
• CA 125- elevated(>65U/ml) in 80% of women with EOC
• CT or MRI to plan management
• Exclude extra-ovarian primary- esp. from gastric, colorectal, appendiceal, breast, endometrial
![Page 11: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/11.jpg)
Assessment
• Ca125
• HE4
• Ca19.9
• ROMA-Sensitivity- 86%, specificity-84%
• RMI- Sensitivity- 78%, Specificity- 87%
![Page 12: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/12.jpg)
Assessment
• Nutritional assessment
• Other medical Issues
• Full blood count
• Liver and renal function tests
• Coagulation tests
• Chest radiograph
• Electrocardiogram
• Computed tomography (CT) of the abdomen
• Plural effusions may require drainage to aid respiratory function
![Page 13: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/13.jpg)
Assessment
• Primary cytoreduction vs Neoadjuvant chemo
• Tissue diagnosis prior to Neoadjuvant chemo
• Stage at presentation –• I (23 to 33 percent),
• II (9 to 13 percent),
• III (46 to 47 percent),
• IV (12 to 16 percent)
![Page 14: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/14.jpg)
Treatment
• Stage if no evidence of macroscopic or radiological metastatic disease
• Debulking surgery
• Limitations to optimal cyoreduction-• Comorbidities
• Small bowel mesenteric disease
• Porta hepatis disease
![Page 15: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/15.jpg)
Cytoreduction
• Cytoreductive surgery is the cornerstone of therapy
• Benefits of aggressive cytoreduction• Reduce tumour burden for optimal chemo response
• Reduce disease related symptoms
• Improves immune competence by reducing cytokines produced by tumour
• Debulking procedures only improve survival when optimal cytoreduction can be achieved
• Women with optimally resected tumour have, on average, a 20-month improvement in median survival compared to those with suboptimal resection
![Page 16: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/16.jpg)
Cytoreduction
• Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era : A Meta-AnalysisRobert E. Bristow, Rafael S. Tomacruz, Deborah K. Armstrong, Edward L. Trimble, and F.J. Montz
• 53 studies• 6885 patients• Each 10% increase in cytoreduction results in a 5.5% increase in median
survival • Therefore require an “expert center” is an optimal resection rate of at least
75%• The specialty of the operating surgeon is an independent determinant of
survival for women with ovarian carcinoma
![Page 17: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/17.jpg)
Cytoreduction
• The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancerE. Eisenhauer
• Retrospective• 296 patients• Cytoreduction to no visible disease associated with-
• Improved response to chemo• Less platinum resistance
• Improved disease free and overall survival
![Page 18: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/18.jpg)
Neoadjuvant chemotherapy
• Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
• EORTC 55971 trial
• No difference in outcome
• Reduced morbidity
![Page 19: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/19.jpg)
Adjuvant treatment
• Chemotherapy- Carbo/Taxol
• IP Chemo
• Dose dense
• Targeted therapies
![Page 20: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/20.jpg)
![Page 21: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/21.jpg)
![Page 22: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/22.jpg)
![Page 23: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/23.jpg)
![Page 24: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/24.jpg)
![Page 25: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/25.jpg)
The ne w eng l and jour na l of medicine
Pro
bab
ility
of
Rec
urr
ence
-fre
eSu
rviv
al
0.1
0.00 3 4 5
Years since Randomization
A Recurrence-freeSurvival
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
123122
4867
1831
715
57
25
Surgery
Surgery plus HIPEC
Pro
bab
ility
o
fSu
rviv
al
B
Overall Survival
1.0
0.9
0.8
0.7
0.6
No. at Risk
Surgery 123 103 70 44 27 12
Surgery plus
HIPEC
122 108 79 56 37 20
Surgery plus HIPEC
HyperthermicIntraperitoneal Chemotherapy
in OvarianCancer
W.J. van Driel, et al 2018
Years since Randomization
![Page 26: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/26.jpg)
![Page 27: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/27.jpg)
![Page 28: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/28.jpg)
Prophylaxis
• 13-15% due to BRCA
• BRCA 1- 40% risk
• BRAC 2- 15% risk
• Consider risk reduction surgery at 35-40 for BRCA 1, and 40-45 for BRCA 2
![Page 29: Symptoms, assessment and treatment options for …...2019/10/13 · Symptoms, assessment and treatment options for Ovarian Cancer Dr. Naven Chetty Gynaecological Oncologist Queensland](https://reader034.vdocument.in/reader034/viewer/2022042119/5e97dd50b01115017d572e87/html5/thumbnails/29.jpg)
Screening
• UK Collaborative Trial of Ovarian Cancer Screening study
• 202,638 postmenopausal women
• Ca125, followed by U/S vs no screening
• 12/25 invasive tumours stage I or II
• No mortality reduction
• 10 women had surgery for benign lesions for every 1 cancer found
• 641 women would need to be screened annually for 14 years to prevent 1 death from ovarian cancer